Company Profile
HeartBeam Stock Price, News & Analysis
- Ticker:
- BEAT
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
0.58 USD (-4.48%)
Close
Last updated: July 13, 2026 at 00:00
33.58M USD
Market cap
Why the stock is moving
BEAT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
HeartBeam is a cardiometabolic biopharmaceutical company focused on long-duration disease areas where efficacy, access, and long-term adoption all matter to investors.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, HeartBeam is followed within the cardiometabolic universe for its exposure to chronic-disease treatment demand.
Business Model Characteristics
HeartBeam follows a pipeline-and-launch model where clinical data, label expansion, and the commercial path for chronic-disease programs all shape the story.
Position Within the Biotechnology Landscape
Compared with acute-catalyst biotech names, HeartBeam sits in a more adoption-driven part of the landscape where commercial execution and follow-on data matter together.
Future catalysts
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
- 03
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 04
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of HeartBeam (BEAT)?
HeartBeam (BEAT) most recently closed at 0.58 USD, a -4.48% move versus the previous session.
What is the market cap of HeartBeam (BEAT)?
HeartBeam currently has a market capitalization of 33.58M USD on BioPharmSignal.
What does HeartBeam do?
HeartBeam is a cardiometabolic biopharmaceutical company focused on long-duration disease areas where efficacy, access, and long-term adoption all matter to investors.
On which exchange is BEAT stock listed?
HeartBeam (BEAT) is associated with NASDAQ, United States, Biotechnology.
What is HeartBeam?
HeartBeam is a cardiometabolic biopharmaceutical company focused on long-duration disease areas where efficacy, access, and long-term adoption all matter to investors.
Which conditions is HeartBeam targeting with HeartBeam?
HeartBeam is associated with metabolic disease based on its company overview and current catalyst commentary.